The National Heart, Lung, and Blood Institute (NHLBI) awarded a $162,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Connecticut. The grant will fund a 12-week proof-of-concept study testing a technology-delivered mindful walking intervention to reduce stress, increase physical activity, and lower blood pressure in Black women with hypertension. The project aims to address disparities in hypertension and physical activity rates among...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,438,522 to Rutgers, The State University of New Jersey to investigate biopsychological processes linking psychosocial stress and cardiometabolic health among 300 older foreign-born Chinese Americans. The study aims to determine how daily negative emotions, cortisol secretion, and sleep quality mediate the association between social isolation and outcomes like...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $147,486 to The Medical University of South Carolina to investigate the mechanisms linking stress and aortic pathology. The research aims to: 1) Examine the role of sympathetic overactivation, TGF-β signaling, and novel pathways in stress-induced extracellular matrix (ECM) remodeling, and 2) Evaluate whether the neurosteroid allopregnanolone can suppress...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $165,364 to The Broad Institute, Inc. to conduct research focused on integrating novel contextual and genomic blood pressure measures to enhance cardiovascular disease prediction and management in young adults aged 18-39 years. The key objectives of this 2-year project are to: 1) identify novel ambulatory blood pressure patterns that capture dynamic responses to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,321,108 Project Grant under CFDA 93.837 (Cardiovascular Diseases Research) to New York University School of Medicine to conduct transdisciplinary implementation research on a strategy called PT4A. PT4A integrates peer-based medication delivery, peer coaching, and health information technology to improve medication adherence and reduce blood pressure among patients with uncontrolled hypertension in Western Kenya. The study aims to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded The Trustees of Columbia University in the City of New York a $821,982 Project Grant under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837). The grant, awarded on July 15, 2024, will fund a 5-year research project to investigate variability in sleep timing as a potential new risk factor for cardiovascular disease (CVD) among women. The study will leverage two racially and ethnically diverse cohorts of women...
The National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $727,080 Project Grant to the University of South Carolina to investigate the neurogenic mechanisms underlying the relationship between psychosocial stress, postpartum cardiovascular disease, and postpartum depression. The 4-year research project aims to delineate how stress-induced mitochondrial dysfunction in the medial prefrontal cortex contributes to postpartum...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $786,060 to Vanderbilt University Medical Center to study how hypertension induces "trained immunity" in myeloid cells, potentially contributing to chronic inflammation and increased risk of atherosclerotic cardiovascular disease. The research aims to determine how hypertension rewires the epigenome of myeloid progenitors, leading...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $190,491 to Beth Israel Deaconess Medical Center, Inc. to conduct research on plasma protein markers of the blood pressure response during exercise and their relation to incident hypertension and cardiovascular disease. The project aims to identify circulating proteins associated with exercise blood pressure that could serve as predictive markers for future...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $774,229 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Kaiser Foundation Hospitals to conduct a large longitudinal cohort study on cardiometabolic risks among adolescents and young adults (AYA). The study aims to describe the incidence and trends of cardiometabolic conditions like hypertension, prediabetes, and fatty liver disease in diverse AYA populations, examine how childhood/adolescent BMI...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,709,341.45 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of Columbia University in the City of New York to conduct a 1-week daily diary study. The study aims to estimate the influence of intersectional anticipated and vicarious stigma on home blood pressure, and examine potential mediating mechanisms such as salivary stress biomarkers and anxiety. The research will recruit a diverse sample of 400 adults without diagnosed hypertension or cardiovascular disease, and collect data through structured electronic diaries, saliva samples, actigraphy, and home blood pressure monitoring. This study represents the first robust examination of how anticipated and vicarious stigma, beyond enacted stigma, may impact blood pressure in real-world environments. The award period runs from September 1, 2024 to March 21, 2025.